Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Cancers (Basel) · 2022 · PMC8869808 · PMID 35205729

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, patients treated with a combination of PD1 inhibitors and chemotherapy showed a trend to a better response than those treated only with chemotherapy, underlining the potential synergy among the two treatments [ 16 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.